Project Grant R43HL184803
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $591K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Auburndale, MA 02466, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Lynntech Inc. $319,607 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and demonstrate the feasibility of BreathWise, an AI-driven early-warning system for COPD exacerbations. BreathWise integrates multimodal physiological, behavioral, and environmental sensing with machine learning-based predictive analytics to identify COPD patients at imminent risk of exacerbation. The system continuously...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Institute of Environmental Health Sciences awarded Spiromatics, Inc. $471,544 on September 16, 2025, under the Medical Library Assistance program (CFDA 93.879) to develop a portable, handheld spirometer equipped with audiovisual coaching for improved detection and monitoring of obstructive lung disease. Spiromatics is developing novel diagnostic methods and a patient-friendly measurement approach that detects airflow limitation in approximately 11 percent more individuals than...
- The National Heart, Lung, and Blood Institute awarded Actiox LLC $699,468 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for development of a wearable microneedle-based biosensor for continuous cardiac troponin I monitoring. The assistance type is a Project Grant. Actiox will develop and optimize an electrochemical aptamer-based sensor integrated with microneedle arrays capable of real-time, ultra-sensitive monitoring of cardiac troponin I in interstitial...
- The National Heart, Lung, and Blood Institute awarded Nightingale Labs Corp $1.368 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to commercialize non-contact cardiopulmonary monitoring technology for heart failure management. Nightingale Labs is developing a fully automated, non-contact home bed sensor platform that monitors cardiopulmonary physiology without requiring active patient participation, aimed at detecting clinical deterioration in heart...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $197,634 in project grant funding on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This K23 mentored research award funds investigation of inhaled nitric oxide (INO) responder and non-responder phenotypes in persistent pulmonary hypertension of the newborn (PPHN) using electrical impedance tomography (EIT)...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $331,340 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate dynamic free-breathing 129Xe MRI as a non-invasive functional lung imaging tool for pediatric populations including neonates, infants, toddlers, and young children. The project addresses limitations of current clinical assessment methods for pediatric lung diseases such as...
- The National Heart, Lung, and Blood Institute awarded Nytricx, Inc. $314,337 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer nitric oxide-releasing intravascular catheters with solid slippery surfaces designed to combat infection and thrombosis in short-term applications. Nytricx, Inc., a self-certified small disadvantaged business headquartered in Athens, Georgia, specializes in nitric oxide release polymer technologies for advanced medical...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of North Carolina at Chapel Hill $420,281 on April 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to design, fabricate, and test a needle-type nitric oxide sensor in a swine model as a function of diabetes disease state. The project will establish the analytical performance of implantable nitric oxide sensors with robust...
- The National Heart, Lung, and Blood Institute awarded Linshom Medical, Inc. $322,277 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct clinical evaluation of an alarm-activated detection system for early intervention of emerging respiratory decline using Linshom's FDA-cleared Continuous Predictive Respiratory Sensor (CPRS). The funding supports clinical development activities demonstrating the health economic value of the CPRS system, which...